VTYX - CIK 0001851194
The table below shows Ventyx Biosciences, Inc.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| R&D | $117.00M | $175.77M | $87.74M | $58.48M | $6.37M |
| SG&A | $31.45M | $32.23M | $25.40M | $8.67M | $684.00K |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$148.45M |
| -$207.99M |
| -$113.14M |
| -$67.15M |
| -$7.05M |
| Income tax | - | - | - | - | - |
| Net income | -$135.12M | -$192.96M | -$108.43M | -$83.75M | -$28.17M |
| EPS (diluted) | -$1.97 | -$3.30 | -$2.07 | -$6.65 | - |